6月15日,三叶草生物公告:已向国光生物发出通知终止四价流感疫苗的合作。国光生物是一家中国台湾的疫苗企业,生产的四价流感疫苗2022年1月在中国大陆获批上市。三叶草2023年2月与国光生物签订协议,独家代理四价流感疫苗AdimFlu-S。仅一年多的时间,三叶草生物就结束了合作。至于终止原因,三叶草生物解释是“市场情况出现重大变化”。三叶草生物此前只有一款新冠疫苗上市销售,所以很重视这款引进的...
Source Link6月15日,三叶草生物公告:已向国光生物发出通知终止四价流感疫苗的合作。国光生物是一家中国台湾的疫苗企业,生产的四价流感疫苗2022年1月在中国大陆获批上市。三叶草2023年2月与国光生物签订协议,独家代理四价流感疫苗AdimFlu-S。仅一年多的时间,三叶草生物就结束了合作。至于终止原因,三叶草生物解释是“市场情况出现重大变化”。三叶草生物此前只有一款新冠疫苗上市销售,所以很重视这款引进的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.